Do You Believe in Insmed’s INSM) Long-Term Potential Despite Short-Term Challenges?

Artisan Partners, an investment management firm, recently published its second-quarter 2026 investor commentary for the Artisan Global Opportunities Strategy. The letter revealed that the portfolio delivered strong absolute returns of 12.65% (net) but trailed the benchmark due to its underweight exposure to information technology and overweight position in healthcare.

Despite these challenges, the firm remains optimistic about Insmed Incorporated (NASDAQ:INSM), a clinical-stage biotechnology company specializing in pulmonary diseases.

Insmed's BRINSUPRI® therapy has seen a rapid launch with robust patient uptake and encouraging third-party data. Although Q1 sales were modestly below investor expectations, Artisan Global Opportunities Strategy believes the underlying launch trajectory remains promising. They view BRINSUPRI® as a significant long-term opportunity, with the therapy showing promising tolerability and on track for blockbuster-level sales.

The fund has trimmed its position in Insmed Incorporated, aligning with the belief that certain AI stocks offer greater upside potential and carry less downside risk. Currently, Insmed Incorporated is not on the list of the 40 Most Popular Stocks Among Hedge Funds. Despite this, the company has attracted the attention of 88 hedge fund portfolios as of the end of the second quarter, up from 67 in the previous quarter.

Artisan Global Opportunities Strategy highlights Insmed's recent stock price jump of 33.86% following a 296% increase in total revenues to $425.5 million. This surge was primarily driven by a $309.2 million contribution from the drug Brinsupri. The firm encourages readers to explore their free report on the best short-term AI stock for an extremely undervalued investment opportunity.